Cargando…

Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor

Background: Because reports on the management of recurrent granulosa cell tumor have been sparse, a consensus as to which patients should undergo surgical resection and which patients should be considered for chemotherapy has not been established. Methods: A total of 21 tumor recurrences in eight pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakai, Hidekatsu, Koike, Eiji, Murakami, Kosuke, Takaya, Hisamitsu, Kotani, Yasushi, Nakai, Rika, Suzuki, Ayako, Aoki, Masato, Matsumura, Noriomi, Mandai, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956330/
https://www.ncbi.nlm.nih.gov/pubmed/31739624
http://dx.doi.org/10.3390/healthcare7040145
_version_ 1783487134615732224
author Nakai, Hidekatsu
Koike, Eiji
Murakami, Kosuke
Takaya, Hisamitsu
Kotani, Yasushi
Nakai, Rika
Suzuki, Ayako
Aoki, Masato
Matsumura, Noriomi
Mandai, Masaki
author_facet Nakai, Hidekatsu
Koike, Eiji
Murakami, Kosuke
Takaya, Hisamitsu
Kotani, Yasushi
Nakai, Rika
Suzuki, Ayako
Aoki, Masato
Matsumura, Noriomi
Mandai, Masaki
author_sort Nakai, Hidekatsu
collection PubMed
description Background: Because reports on the management of recurrent granulosa cell tumor have been sparse, a consensus as to which patients should undergo surgical resection and which patients should be considered for chemotherapy has not been established. Methods: A total of 21 tumor recurrences in eight patients with granulosa cell tumor were reviewed. Results: Surgery was performed as the main treatment for 13 recurrences, while chemotherapy was chosen as the main treatment for eight recurrences. Complete tumor resection could be accomplished in 13 of 16 surgeries (81.3%), which include all the ten recurrences without involvement of liver or diaphragm and without ascites. The number of recurrent masses was significantly higher in the early recurrence group (progression free survival < 2 years) than in the late recurrence (progression free survival > 2 years). All cases with a solitary recurrent tumor at an extra-peritoneal site presented a significantly longer progression free survival. Conclusions: For patients with recurrent granulosa cell tumor, surgery may provide the best disease control. In cases with complete resection, the number of recurrent masses was the predictive factor for the next recurrence, and adjuvant chemotherapy might be considered in such cases.
format Online
Article
Text
id pubmed-6956330
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69563302020-01-23 Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor Nakai, Hidekatsu Koike, Eiji Murakami, Kosuke Takaya, Hisamitsu Kotani, Yasushi Nakai, Rika Suzuki, Ayako Aoki, Masato Matsumura, Noriomi Mandai, Masaki Healthcare (Basel) Article Background: Because reports on the management of recurrent granulosa cell tumor have been sparse, a consensus as to which patients should undergo surgical resection and which patients should be considered for chemotherapy has not been established. Methods: A total of 21 tumor recurrences in eight patients with granulosa cell tumor were reviewed. Results: Surgery was performed as the main treatment for 13 recurrences, while chemotherapy was chosen as the main treatment for eight recurrences. Complete tumor resection could be accomplished in 13 of 16 surgeries (81.3%), which include all the ten recurrences without involvement of liver or diaphragm and without ascites. The number of recurrent masses was significantly higher in the early recurrence group (progression free survival < 2 years) than in the late recurrence (progression free survival > 2 years). All cases with a solitary recurrent tumor at an extra-peritoneal site presented a significantly longer progression free survival. Conclusions: For patients with recurrent granulosa cell tumor, surgery may provide the best disease control. In cases with complete resection, the number of recurrent masses was the predictive factor for the next recurrence, and adjuvant chemotherapy might be considered in such cases. MDPI 2019-11-14 /pmc/articles/PMC6956330/ /pubmed/31739624 http://dx.doi.org/10.3390/healthcare7040145 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nakai, Hidekatsu
Koike, Eiji
Murakami, Kosuke
Takaya, Hisamitsu
Kotani, Yasushi
Nakai, Rika
Suzuki, Ayako
Aoki, Masato
Matsumura, Noriomi
Mandai, Masaki
Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
title Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
title_full Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
title_fullStr Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
title_full_unstemmed Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
title_short Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
title_sort clinical determinants affecting indications for surgery and chemotherapy in recurrent ovarian granulosa cell tumor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956330/
https://www.ncbi.nlm.nih.gov/pubmed/31739624
http://dx.doi.org/10.3390/healthcare7040145
work_keys_str_mv AT nakaihidekatsu clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT koikeeiji clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT murakamikosuke clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT takayahisamitsu clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT kotaniyasushi clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT nakairika clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT suzukiayako clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT aokimasato clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT matsumuranoriomi clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor
AT mandaimasaki clinicaldeterminantsaffectingindicationsforsurgeryandchemotherapyinrecurrentovariangranulosacelltumor